News & Updates

NovaHep wins a major EU-grant and becomes a member of the SME Champions League

Gothenburg, Sweden – June,12 2017

NovaHep is happy to announce that it has won a grant of 2 184 603,75 Euro from the Horizon 2020 SME instrument of the European Commission for its project “Personalized Tissue-Engineered Veins (P-TEV) as the first Cure for Patients with Chronic Venous Insufficiency”. This funding will support the Phase I/II clinical development of NovaHep’s lead product.

“The SME Instrument funding represents an important element on our way to the next level of development and we are very proud to have been promoted to the SME Champions league. The NovaHep team is very thankful for this reward of our rock-solid commitment and we are highly motivated to make this project a great success. This funding will facilitate our high ambitions to develop novel products that can help millions of patients with today incurable diseases.” says Dr. Petter Björquist, CEO of NovaHep.

NovaHep is a biotechnology company, located in Gothenburg, Sweden. The company generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogeneic tissue is patient-individualized by a combination of DC (decellularization) and RC (reconditioning/recellularization) processes. NovaHep’s development pipeline comprises products in the areas of vascular regeneration and peripheral nerve repair.

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over 7 years (2014 to 2020. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation and to take great ideas from the lab to the market.

 

For more information, please contact: Petter Björquist, CEO, petter.bjorquist@novahep.com

NovaHep and its partners RISE and University of Gothenburg receive grant from Vinnova and Region Västra Götaland

Gothenburg, June 7, 2017

University of Gothenburg, Research Institutes of Sweden (RISE) and NovaHep were granted support for a collaborative project with the title “Personalized Tissue Engineered Arteries (P-TEA) as a Novel Cure for Cardiovascular Disease”. The project’s total budget of 2,3 million SEK will be supported by Swelife/Medtech4Health and by the region Västra Götaland with 700 000 SEK each. The project will perform a proof of concept study in large animals, characterize P-TEA in vitro to generate preclinical documentation and undertake a technology transfer to industrial GMP production of P-TEA.

“We are very happy about this grant, because it allows us to generate important safety data to bring our product one step closer to the phase of clinical development. Furthermore, this will be a key project for the whole field of regenerative medicine, generating unique in vivo data. Together with our strong and committed partners, we will make our ambitions become true in this innovation project.” says Dr. Petter Björquist. CEO of NovaHep.

NovaHep is a regenerative medicine company, located in Gothenburg, Sweden. The company generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogeneic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. NovaHep’s development pipeline comprises products in the areas of vascular regeneration and peripheral nerve repair.

The University of Gothenburg is one of the largest universities in the Nordic countries with 37000 students and 6000 staff members and Sahlgrenska University Hospital is associated with the university as a teaching hospital.

RISE Research Institutes of Sweden is fully owned by the Swedish state. RISE supports all manner of innovative processes, and is instrumental in developing the future-proofing of products, technologies, and services. Through collaboration with academia, industry and the public sector, RISE contributes to the competitiveness of the Swedish business community on an international level.

Swelife and Medtech4Health are national strategic innovation programs, funded by the Swedish Government via the Swedish innovation agency, Vinnova. Swelife and Medtech4Health support projects where healthcare, academia and industry collaborate across organizational boundaries and between regions to achieve long-term effects that benefit Swedish Life Science and, in turn, public health.

Region Västra Götaland is a region in West Sweden with the assignment to contribute to a thriving region as a good place to live and work and for future generations to grow up in.

 

NovaHep’s new information strategy

Do you feel like you don’t know enough about what’s going on at NovaHep?

We will remedy that by improving the flow of news, about the company and it’s achievements on the web and in social media.

 

 

Edvard Nordfors new CFO of NovaHep AB

Edvard Nordfors will assume the position as Chief Financial Officer at NovaHep AB, starting July 1, 2016.

 

“We are very pleased to announce that Edvard Nordfors will be joining our team to assume an instrumental role in NovaHep’s continued development and path towards commercialization. Edvard brings extensive international experience in financial management, M&A and investments from both large and small companies across several industries, including the life science industry”, says NovaHep CEO Petter Björquist.

 

NovaHep AB is a Swedish regenerative medicine company with a unique technology for engineering a broad range of biocompatible tissues and organs. NovaHep’s products in development rely on patient-individualization of donated organs and tissues by applying advanced, proprietary technology for de- and recellularization. The current focus lies on preparing for a clinical trial, the first of its kind in the world, with veins tissue-engineered by NovaHep. NovaHep is located in central Gothenburg in close vicinity to Sahlgrenska University Hospital.

 

For further information, please contact Petter Björquist at petter.bjorquist@novahep.com or call +46 705 97 92 96.

NovaHep enters into commercial license agreement with GemVax Technology Co., covering Korea, Japan and China

PRESS RELEASE

January 25, 2016

 

NovaHep has entered into a commercial license agreement with GemVax Technology Co. Ltd. (GemVax).

 

“We are very pleased with this agreement as it signifies a commercial validation of our technology and knowhow, with GemVax as a valuable partner for these important markets of ours”, says Dr. Petter Björquist, CEO of NovaHep AB.

 

In addition, the agreement entails know-how transfer related to NovaHep’s personalized tissue-engineered veins as basis for GemVax bringing them to market in Korea, Japan and China, leveraging on its expertise within development and commercialization.

 

We greatly value NovaHep’s technology, which is truly unique.  We are very happy with this agreement as we anticipate a vast potential with NovaHep’s tissue-engineered veins in Korea, Japan and China”, says Jay Kim, CEO of GemVax Technology Co., Ltd.

 

NovaHep continues to progress with its preparations for the upcoming Scandinavian clinical trial related to its personalized tissue-engineered vein with competent valves, targeting the disease Chronic Venous Insufficiency, in addition to its R&D activities within its promising pipeline of other tissue-engineered products.

 

For any questions related to this matter, please contact CEO Petter Björquist (+46 705 97 92 96).

NovaHep lectures at the Technical University of Denmark (DTU)

NovaHep was invited to lecture at the Technical University of Denmark (DTU) on October 27 2015, at the lecture session on stem cells hosted by the the student organization Society for Biological Engineering.

 

NovaHep featured in magazine The Forefront of Life Science

Published: September 2015
Source: http://np.netpublicator.com/netpublication/n64753875

 

Excerpt

Transplantation Without Immunosuppression – NovaHep AB provides a unique and ground-breaking technology for biological engineering of individualised blood vessels and other organs for transplantation. The technology circumvents the patient’s immune system, thereby avoiding the need for immunosuppressive drugs.

 

To read the full article go to the URL above or click the image below.

 

NovaHep_article_TheForefrontofLifeScience

NovaHep appears on stemcellassays.com’s “10 companies to watch”-list

Published: 2014-10-24
Source: http://stemcellassays.com/2015/07/10-companies-watch-5/

 

Excerpt

“RegenMed startup from Sweden. The company is developing the concept of whole organ bioengineering by utilizing decell-recell technology. The current focus in on blood vessels and liver. I like the vision of the company about recycling human organs. The company on a way to first clinical trial.”

 

Oslo University Hospital, IRW Consulting and NovaHep AB to prepare for and run clinical trial in Oslo

NovaHep AB has signed an agreement with Swedish contract research organisation IRW Consulting AB for an upcoming clinical trial in Oslo, Norway. Together with principal investigators at Oslo University Hospital, a first clinical trial using NovaHep´s personalised tissue-engineered vein (P-TEV) will be planned during 2015. This clinical trial, targeting the indication chronic venous insufficiency (CVI), is the first of its kind in the world and is sponsored by NovaHep. The P-TEV will be produced in a GMP accredited facility at Sahlgrenska University Hospital in Gothenburg for use by the National Unit for Reconstructive Deep Venous Surgery – Norwegian Venous Insufficiency (NOVI) at Oslo University Hospital, where the clinical trial will be performed. IRW Consulting will manage the study and will be responsible for monitoring, data management, pharmacovigilance and biostatistics. This study will be the first cornerstone in NovaHep’s portfolio of tissue-engineered products.

 

About NovaHep AB:

NovaHep AB is a Swedish regenerative medicine company with a unique technology for developing a broad range of biocompatible tissues and organs. NovaHep’s products in development rely on patient-individualisation of donated organs and tissues by applying advanced, proprietary stem cell technology. NovaHep has shown proof-of-concept with successful transplantations carried out at Sahlgrenska University Hospital in 2011 and 2012.

 

About IRW Consulting:

IRW is a Nordic Contract Research Organization (CRO) with more than 15 years of experience in conducting clinical trials, non-interventional Studies (NIS) and medical device investigations. IRW has offices throughout all Nordic countries, as well as an extensive network in the rest of Europe and the US.

 

About the National Unit for Reconstructive Deep Venous Surgery – Norwegian Venous Insufficiency (NOVI), Oslo University Hospital:

NOVI falls under the Department of Vascular Surgery at Oslo University hospital, which is a highly specialised hospital in charge of extensive regional and local hospital assignments and the provision of high quality services for the citizens of Oslo. The hospital also has a nationwide responsibility for a number of national and multi-regional assignments and has several national centres of competence. The hospital carries out advanced patient treatment, research and trial treatments, give advice and provide education on international levels. The hospital is Scandinavia’s largest, each year carrying out more than 1.2 million patient treatments (source: oslo-universitetssykehus.no).

Raimund Strehl new CTO of NovaHep AB

PRESS RELEASE

June 10, 2015

 

Dr. Raimund Strehl will assume the position as Chief Technology Officer at NovaHep AB, starting August 1, 2015.

“We are very pleased to announce that Raimund Strehl will be joining our team. With an impressive network and extensive experience within the industry of stem cells and regenerative medicine, Raimund will be a key person in NovaHep’s continued efforts on the path towards providing a range of personalised tissues and organs for reconstructive surgery. Relying on comprehensive competencies within process development and industrialisation of regenerative medicine, Raimund has taken several stem cell products to market. He will be instrumental in realising our tissue-engineered veins as our targeted first application”, says NovaHep CEO Petter Björquist.

NovaHep AB is a Gothenburg-based Swedish regenerative medicine company with a unique technology for developing a broad range of biocompatible tissues and organs. NovaHep is addressing the major shortcomings and drawbacks associated with organ transplantation of today, such as a lack of suitable organs available, the adverse side-effects of immunosuppressive drugs, and the oftentimes need for repeated surgery. Objectives are to provide for improved quality of life for patients worldwide, and cost-effective care for hospitals, healthcare-providers and society. NovaHep’s products in development rely on patient-individualisation of donated organs and tissues by applying advanced, proprietary stem cell technology. NovaHep has shown proof-of-concept with successful transplantations carried out at Sahlgrenska University Hospital in 2011 and 2012.

For further information, please contact Petter Björquist at petter.bjorquist@novahep.com or call +46 705 979296.

Show Buttons
Hide Buttons